Table 3.

Polymeric-based miRNA delivery systems.

Delivery System	miRNA	Therapeutic Application	Polymers	Particle Size	Refs.
Polyplexes	miR-210	Ischemic heart disease	PEI-Deoxycholic acid (DA)	100–180 nm	[86]
	anti-miR 21	Breast cancer	PEI-PLL	300 nm	[87]
	miR-34a	Prostate tumor	Chitosan	N/A	[107]
	miR-34a	Breast cancer	Chitosan/ Hyaluronic acid	185–214 nm	[113]
	miR-34a	Breast cancer	Hyaluronic acid/ Protamine sulfate	201 nm	[114]
	miR-124	Neurodegenerative disorders	Chitosan	222 nm	[115]
	miR-145	Breast cancer	Chitosan	190 nm	[108]
	miR-145	Breast cancer	Chitosan/Carboxymethyl dextran (CMD)	30–695 nm	[116]
	miR-181a	Chronic myeloid leukemia	Pullulan spermine (PS)	200–250 nm	[117]
	miR-200 miR 141	Breast cancer	Chitosan	296–380 nm	[109]
	miR-126	Angiogenesis	Trimethyl (TMC) chitosan	98–342 nm	[118]
PLGA NPs	anti-miR10b anti-miR 21	Breast cancer	PLGA-b-PEG	100-200 nm	[91]
	miR-34a	Breast cancer	PLGA-PLL	122 nm	[85]
	miR-34a	Multiple myeloma	PLGA-Chitosan	160 nm	[110]
	miR-150	Pancreatic cancer	PLGA	183 nm	[92]
Dendrimers	miR-194-5p miR-214-3p anti-miR-122-5p	Myocardial Infarction	PAMAM-His	60 nm	[99]
	anti-miR-21	Glioblastoma	PAMAM	100 nm	[100]

Abbreviations: PEI: Polyethyleneimine; PLL: poly L-Lysine; PLGA: polylactic-co-glycolic acid; PEG: polyethylene glycol; PAMAM: polyamidoamine; His: Histidine; N/A: not applicable.